skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
Bosutinib (Code C60809)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Bosutinib

Definition: A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.

Display Name: Bosutinib

Label: Bosutinib

NCI Thesaurus Code: C60809 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1831731  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
SKI 606

External Source Codes: 
CAS Registry Number 380843-75-4 (see NLM ChemIDplus info)
FDA UNII Code 5018V4AEZ0
ChEBI ID CHEBI:39112 (see ChEBI info)
PDQ Closed Trial Search ID 467222
PDQ Open Trial Search ID 467222 (check for NCI PDQ open clinical trial info)
UMLS CUI C1831731

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C26H29Cl2N5O3
code C60809
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Bosutinib
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom